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S100BAlthough inﬂammation may be a physiological defense process, imbalanced neuroinﬂammation has been as-
sociated with the pathophysiology of brain disorders, including major depression and schizophrenia. Activat-
ed glia releases a variety of pro-inﬂammatory cytokines that contribute to neuronal dysfunction. Elevated
levels of S100B, a glia derived protein, have been observed in the serum and CSF of schizophrenic patients
suggesting a glial role in the disease. We evaluated whether S100B secretion (in C6 glioma cells and hippo-
campal slices in Wistar rats) could be directly modulated by the main inﬂammatory cytokines (IL-1β,
TNF-α, IL-6 and IL-8) altered in schizophrenia, as well as the possible involvement of mitogen-activated pro-
tein kinase (MAPK) pathways in these responses. We also investigated the effects of typical and atypical an-
tipsychotic drugs on glial cytokine-induced S100B release. Our results suggest that S100B secretion is
increased by pro-inﬂammatory cytokines via MAPK and that oxidative stress may be a component of this
modulation. These results reinforce the idea that the S100B protein is involved in the inﬂammatory response
observed in many brain diseases, including schizophrenia. Moreover the antipsychotics, haloperidol and ris-
peridone, were able to inhibit the secretion of S100B following IL-6 stimulation in C6 glioma cells.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Neuroinﬂammation plays a critical role in different neurological
and psychiatric diseases. Although inﬂammation may be a physiolog-
ical defense process, beneﬁcial for repair and recovery of the central
nervous system (CNS) (Wee Yong, 2010), imbalanced inﬂammation
has been associated with the pathophysiology of several brain disor-
ders, including Alzheimer's disease, major depression and schizo-
phrenia (Akiyama et al., 2000; Garate et al., 2011; Monji et al.,
2009). The inﬂammatory response in the CNS includes a wide spec-
trum of complex and integrated cellular responses, such as microglial
and astroglial activation. These glial cells, when activated, releases a
variety of pro-inﬂammatory mediators (e.g. cytokines) which can po-
tentially contribute to neuronal dysfunction and result in the progres-
sion of the CNS pathology (Khansari et al., 2009).7′-dichloroﬂuorescein; ELISA,
r signal-regulated kinase, one
FAP, glial ﬁbrillary acidic pro-
erleukin-6; IL-8, interleukin-8;
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vier OA license.Cytokines are involved in regulating the communication between
immune cells, thus, high peripheral and CNS cytokine levels indicate ac-
tivation of the inﬂammatory response. However, these cytokines mod-
ulate not only normal CNS function; abnormal cytokine signaling may
contribute to major acute and chronic CNS diseases (Tansey, 2010). In-
creased levels of pro-inﬂammatory cytokines, such as IL-1β, TNF-α and
IL-6, have been found in individuals with epilepsy and autism (Mansur
et al., 2012) and levels of IL-2 andIL-8 may also be elevated in schizo-
phrenia (Zhang et al., 2002). In fact, meta-analyses have shown consis-
tent alterations of increased IL-1β, IL6, and TNF-α levels in the serum of
schizophrenic patients (Miller et al., 2011; Potvin et al., 2008). Further-
more, animals models using iodinated LPS in pregnant rats show that
the development of schizophrenia-like manifestations in offspring rats
occurs, most probably, due to the effect of cytokines, since cytokines
and not LPS can cross the placenta (Ashdown et al., 2006).
S100B, a calcium-binding protein belonging to the S100 family of
proteins in the CNS is predominantly expressed and secreted by as-
trocytes (Donato, 2001; Donato et al., 2009), exerting paracrine and
autocrine effects on neurons and glial cells. This protein may cross
the blood–brain barrier and concentrations of S100B determined in
serum and/or cerebrospinal ﬂuid (CSF) appear to reﬂect the degree
of injury in brain disorders (Pleines et al., 2001). As such, S100B has
been proposed as a marker of brain damage (Goncalves et al., 2008;
Marchi et al., 2004). S100B seems to be able to modulate cytokine se-
cretion and may also be modulated by pro-inﬂammatory cytokines
(Edwards and Robinson, 2006; Schmitt et al., 2007). Moreover,
some studies have demonstrated a signiﬁcant correlation between
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disorders (Ashraf et al., 1999; Steiner et al., 2009). However, the idea
that S100B may be considered to be a cytokine remains controversial.
Our previous reports have suggested that S100B may be an impor-
tant component in neuroinﬂammation. We have demonstrated that
S100B secretion is induced by IL-1β, mediated by MAPK–ERK signal-
ing, in astrocyte cultures, C6 glioma cells and acute hippocampal
slices (de Souza et al., 2009). More recently, we showed that S100B
secretion is stimulated by intracerebroventricular lipopolysaccharide
(LPS) administration and that LPS directly stimulates the secretion
of S100B from astrocytes and hippocampal slices (Guerra et al., 2011).
The presence of elevated S100B levels, observed in the serum and
CSF of schizophrenic patients (Lara et al., 2001; Rothermundt et al.,
2004; Steiner et al., 2006), as well as the association of the schizophre-
nia with certain haplotypes of the S100B gene involved in increased
S100B expression (Liu et al., 2005), provides further evidence that a
dysfunction of glia cells might present a pathogenic factor in schizo-
phrenia. For this reason, C6 glioma cells have been investigated as tar-
gets of antipsychotic medication (Nardin et al., 2011; Steiner et al.,
2010b). We herein evaluate whether S100B secretion could be directly
modulated by the main inﬂammatory cytokines associated with the
pathophysiology of schizophrenia; IL-1β, TNF-α, IL-6 and IL-8 in C6 gli-
oma cells and acute hippocampal slices, as well as the possible involve-
ment of MAPK pathways in these responses. We also investigate the
effects of these cytokines on GFAP and oxidative stress. Finally, we ex-
plore the effects of typical and atypical antipsychotic drugs on glial
cytokine-induced S100B release.
2. Material and methods
2.1. Animals
For the preparation of hippocampal slices, twelve male 30-day old
Wistar rats were obtained from our breeding colony (Department of
Biochemistry, UFRGS, Porto Alegre, Brazil), were maintained under
controlled light and environmental conditions (12 h light/12 h dark
cycle at a constant temperature of 22±1 °C), and had free access to
commercial chow and water. All animal experiments were carried
out in accordance with the National Institute of Health Guide for the
Care and Use of Laboratory Animals (NIH publication no. 80-23) re-
vised in 1996 and followed the regulations of the local animal housing
authorities.
2.2. Materials
Dulbecco's modiﬁed Eagle's medium (DMEM) and other materials
for cell culture were purchased from Gibco (Belo Horizonte, Brazil).
Interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α),
interleukin-6 (IL-6), interleukin-8 (IL-8), 4-(2-hydroxyethyl)-
piperazine-1-ethanesulfonic acid (HEPES), S100B protein, anti-
S100B antibody (SH-B1), o-phenylenediamine (OPD), Triton X-100,
methylthiazolyldiphenyl-tetrazolium bromide (MTT), Griess re-
agent (modiﬁed), standard glutathione, o-phthaldialdehyde and
dichloroﬂuoresceindiacetate (DCF-DA) were purchased from Sigma
(St. Louis, MO, USA). Polyclonal anti-S100B was purchased from
DAKO (São Paulo, Brazil), anti-GFAP from rabbit and anti-rabbit linked
to peroxidasewere purchased fromGE (Little Chalfont, UnitedKingdom).
Other reagents were purchased from local commercial suppliers
(Sulquímica, Labsul or Biogen; Porto Alegre, Brazil).
2.3. Preparation and incubation of brain slices
Rats were decapitated, their hippocampi were quickly dissected out
and transverse sections (300 μm) were rapidly obtained using a
McIlwain tissue chopper. One slice was placed into each well of a
24-well culture plate. Sliceswere incubated in oxygenated physiologicalmediumcontaining, inmM, 120NaCl, 2.0 KCl, 1.0 CaCl2, 1.0MgSO4, 25.0
Hepes, 1.0 KH2PO4 and 10.0 glucose, pH 7.4, at room temperature. The
medium was changed every 15 min for fresh medium. Following a
120-min equilibration period, slices were incubated in medium plus
IL-1β, TNF-α, IL-6 or IL-8 (0.1, 1 or 10 ng/mL) for 1 h at 30 °C.
2.4. C6 glioma cell culture
A rat glioblastoma cell line (C6 cells)was obtained from the American
Type Culture Collection (Rockville, Maryland, USA). Late passage cells
(i.e. after at least 100 passages)were seeded in 24-well plates at densities
of 104 cells/well, and cultured in DMEM (pH 7.4) supplemented with 5%
fetal bovine serum, 2.5 mg/mL Fungizone® and 100 U/L gentamicin in
5% CO2/95% air at 37 °C. After the cells had reached conﬂuence, the cul-
ture medium was replaced by DMEM without serum in the absence or
presence of IL-1β, TNF-α, IL-6 or IL-8 (0.1, 1 or 10 ng/mL). The inhibitors,
PD98059 (10 μM, MEK inhibitor), SB203580 (10 μM, p38 inhibitor),
SP600125 (10 μM, JNK inhibitor) or SN-50 (50 μg/mL, NF-κB inhibitor),
as well as the antipsychotics, haloperidol (0.3 μM), clozapine (3 μM) or
risperidone (70 nM), were added 15 min before cytokine exposure.
2.5. ELISA for S100B
The S100B concentration was determined in the culture medium
at 15 min, 1, 6, and 24 h; and in the incubation medium of slices at
1 h. Cells were washed and scraped at 24 h for measurement of intra-
cellular S100B content. S100B levels were determined by ELISA, as de-
scribed previously (Leite et al., 2008). Brieﬂy, 50 μL of sample plus
50 μL of Tris buffer were incubated for 2 h on a microtiter plate, pre-
viously coated with anti-S100B monoclonal antibody (SH-B1, from
Sigma). Anti-S100 polyclonal antibody (from DAKO) was incubated for
30 min and then peroxidase-conjugated anti-rabbit antibody was added
for a further 30 min. The color reaction with o-phenylenediamine was
measured at 492 nm. The standard S100B curve ranged from 0.002 to
1 ng/mL.
2.6. ELISA for GFAP
ELISA for GFAP was carried out by coating the microtiter plate
with 100 μL samples containing 20 ng of protein for 24 h at 4 °C. In-
cubation with a polyclonal anti-GFAP from rabbit for 1 h was
followed by incubation with a secondary antibody conjugated with
peroxidase for 1 h, at room temperature. A colorimetric reaction
with o-phenylenediamine was measured at 492 nm. The standard
human GFAP (from Calbiochem) curve ranged from 0.1 to 5 ng/mL.
2.7. Immunocytochemistry and cell morphology
C6 glioma cells were cultured on circular glass cover slips. After 1 h
of IL-6 exposure, cells were ﬁxed for 20 min with 4% paraformaldehyde
in phosphate buffer (PBS, mM): 2.9 KH2PO4; 38 Na2HPO47H2O; 130
NaCl; 1.2 KCl, rinsed with PBS and permeabilized for 20 min in PBS
containing 0.2% Triton X-100. Fixed cells were then blocked for
60 min with PBS containing 5% bovine serum albumin and incubated
overnight with anti-S100B monoclonal antibody from mouse (SH-B1),
1:500 or polyclonal anti-GFAP from rabbit, 1:500. Following incubation
with primary antibodies, the cultures were washed in PBS/triton
0.2% (3×5 min) and incubated for 2 h with the respective secondary
antibody at a 1:1000 dilution: Alexa Fluor 528 (goat anti-mouse-IgG;
red ﬂuorescence) and Alexa 488 (goat anti-rabbit-IgG; green
ﬂuorescence).
2.8. MTT reduction assay
Cells were treated with 50 μg/mL methylthiazolyldiphenyl-
tetrazolium bromide (MTT) for 30 min in 5% CO2/95% air at 37 °C.
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dissolved in DMSO. Absorbance values were measured at 560 and
650 nm. The reduction in MTT was calculated as (absorbance at
560 nm)− (absorbance at 650 nm).
2.9. Lactate dehydrogenase (LDH) assay
Lactate dehydrogenase assay was carried out in 50 μL of extracellu-
larmedium, using a commercial colorimetric assay fromDoles (Goiânia,
Brazil).
2.10. Evaluation of intracellular reactive oxygen species (ROS) production
Intracellular ROS production was detected using the non-ﬂuorescent
cell permeating compound, 2′–7′-dichloroﬂuorescin diacetate (DCF-DA).
DCF-DA is hydrolyzed by intracellular esterases and then oxidized by
ROS to a ﬂuorescent compound, 2′–7′-dichloroﬂuorescein. C6 cells were
treated with DCF-DA (10 μM) for 30 min at 37 °C and rinsed with
DMEMwithout serum. Following DCF-DA exposure, the cells were rinsed
and then scraped into PBSwith 0.2% TritonX-100. Fluorescencewasmea-
sured with a spectrophotometer plate reader (Spectra Max GEMINI XPS,
Molecular Devices, USA) with excitation at 485 nm and emission at
520 nm.
2.11. Glutathione (GSH) Content Assay
GSH levels (nmol/mg protein)weremeasured, as described previous-
ly (Browne and Armstrong, 1998). C6 glioma cell homogenates wereFig. 1. Cytokines increase S100B secretion in acute hippocampal slice preparations. Hippocam
IL-8 (D) at concentrations ranging from 0 to 10 ng/mL for 1 h; S100B was measured by EL
levels of S100B ranged from 0.1 to 0.24 ng/mg total protein. Cell integrity and viability, L
value represents the mean (± standard error) of 6 independent experiments performed in
Dunnett's test, with a signiﬁcance level of pb0.05).diluted in 10 volumes of 100 mM sodium phosphate buffer, pH 8.0,
containing 5 mM EDTA and protein was precipitated with 1.7%
meta-phosphoric acid. Supernatant was assayed with o-phthaldialdeyde
(1 mg/mL methanol) at room temperature for 15 min. Fluorescence
was measured using excitation and emission wavelengths of 350 and
420 nm, respectively. A calibration curve was performed with standard
GSH solutions (0–500 μM).2.12. Nitric oxide (NO) production
NO was determined by measurement of nitrite (a stable oxidation
product of NO), based on the Griess reaction. The Griess reagent was
prepared by mixing equal volumes of 1% sulfanilamide in 0.5 N HCl
and 0.1% N-(1-naphthyl) ethylenediamine in deionized water. The
assay was performed as described (Hu et al., 1996) with modiﬁca-
tions. Brieﬂy, cells were cultured on 96-well plates and, after treat-
ment, the Griess reagent was added directly to the cell culture and
the incubation was maintained under reduced light conditions at
room temperature for 15 min. Samples were analyzed at 550 nm on
amicroplate spectrophotometer. Controls and blanks were run simul-
taneously. Nitrite concentrations were calculated using a standard
curve prepared with sodium nitrite (0–50 μM).2.13. Protein determination
Protein content was measured by Lowry's method using bovine
serum albumin as standard (Peterson, 1977).pal slices from 30-day oldWistar rats were exposed to IL-1β (A), TNF-α (B), IL-6 (C) or
ISA. The line indicates basal secretion, assumed as 100% in each experiment. The basal
DH release (E) and capacity for MTT reduction (F) were analyzed, respectively. Each
triplicate. * Signiﬁcantly different from basal secretion (one way ANOVA followed by
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Parametric data are reported as means±standard error and were
analyzed by one-way ANOVA (followed by Tukey's or Dunnett's test).
Values of pb0.05 were considered to be signiﬁcant.3. Results
Cytokines increase S100B secretion in acute hippocampal slice
preparations. Different concentrations of IL-1β, TNF-α, IL-6 and IL-8
(from 0.01 to 10 ng/mL) were added to hippocampal slices and extra-
cellular S100B was measured at 1 h (Fig. 1A–D). Both IL-6 and TNF-α
were able to increase S100B secretion at concentrations of between
0.1 and 10 ng/mL (pb0.01, ANOVA). However, IL-8 and IL-1β in-
creased S100B secretion only at concentrations of 1 and 10 ng/mL
(pb0.05, ANOVA). No effects were observed at cytokine concentrations
of 0.01 ng/mL (data not shown). To make sure that we were determin-
ing S100B secretion, we evaluated cell integrity and viability in our
preparations bymeasuring LDH release and capacity for MTT reduction,
respectively. No changes in the MTT reduction assay (Fig. 1E, p=0.58)
or LDH release were observed (Fig. 1F, p=0.39).
S100B secretion is also acutely modulated by cytokines in C6 glio-
ma cells. In order to investigate a direct effect of cytokines on glial
cells, we added different concentrations of cytokines (from 0.1 to
10 ng/mL) to C6 glioma cell cultures and extracellular S100B was
measured at 1, 6 and 24 h (Fig. 2). All cytokines, at higher concentra-
tions (10 ng/mL), increased S100B secretion at 1 h, but not at 6 h or
24 h afterwards. This acute effect also was observed with the cytokine
concentration of 1 ng/mL in C6 glioma cells (exceptwith TNF-α) and no
effect was observed at the cytokine concentration of 0.1 ng/mL (except
with TNF-α). Similar assays were also carried out in all C6 glioma prep-
arations, conﬁrming cell viability and integrity (data not shown).Fig. 2. S100B secretion is also acutely modulated by cytokines in C6 glioma cells. S100B secr
and D, respectively). The line indicates basal secretion, assumed as 100% in each experimen
the mean (± standard error) of 6 independent experiments performed in triplicate. * Signiﬁc
signiﬁcance level of pb0.05).Cytokine-stimulated S100B secretion occurs via the MAPK path-
way. To assess the role of the MAPK signaling pathway in the
cytokine-stimulated secretion of S100B, speciﬁc inhibitors of this
pathway were added to the C6 glioma culture. The ERK pathway in-
hibitor, PD98059 (Fig. 3) (pb0.0001, ANOVA), the p38 pathway in-
hibitor, SB203580 (Fig. 4) (pb0.001, ANOVA), and the JNK pathway
inhibitor, SP600125 (Fig. 5) (pb0.001, ANOVA), were all able to pre-
vent cytokine-stimulated S100B secretion, without affecting basal
S100B secretion. A possible involvement of NF-кB mediating S100B
secretion was investigated using a speciﬁc inhibitor of NF-кB, SN-50
peptide (Fig. 6). SN-50 was unable to prevent cytokine-stimulated
S100B secretion. Importantly, this inhibitor per se increased S100B se-
cretion (pb0.05, ANOVA) and therefore it is difﬁcult to afﬁrm wheth-
er this inhibitor prevented, or not, the effect induced by cytokines.
IL-6 increases S100B andGFAP content at 24 h in glioma cells. S100B
and GFAP content in C6 glioma cells were measured after 24 h of expo-
sure to cytokines (IL-1β, TNF-α, IL-6 and IL-8; 10 ng/mL) (Fig. 7A and B,
respectively). S100B intracellular content was increased only by IL-6
(pb0.05, ANOVA). On the other hand, an increase in GFAP content
was observed with all cytokines, except TNF-α (pb0.01, ANOVA). The
increment in both proteins induced by IL-6 was conﬁrmed by immuno-
cytochemistry, without changes in cell morphology (Fig. 7C).
Signals of oxidative stress are observed in C6 glioma cells exposed to
cytokines for 1 h or 24 h. Acute exposure of cytokines (IL-1β, TNF-α,
IL-6 and IL-8; 10 ng/mL for 1 h) increased DCF levels (Fig. 8A,
pb0.005), with the exception of IL-8 (p=0.077) and did not change
NO levels (Fig. 8B, p=0.63). After cytokine exposure for 24 h, we ob-
served a decrease in intracellular content of glutathione in cell cultures
treated with IL-1β and IL-8 (Fig. 8C, pb0.005).
The increase in S100B secretion, induced by IL-6 in C6 glioma cells,
is prevented by antipsychotics. In order to evaluate a protective effect
of antipsychotics on S100B secretion induced by IL-6, we added halo-
peridol (typical antipsychotic), clozapine and risperidone (atypicaletion at 1, 6 and 24 h in C6 glioma cells exposed to IL-1β, TNF-α, IL-6 or IL-8 (in A, B, C
t. The basal levels of S100B ranged from 0.08 to 0.12 ng/mg total protein. Each value is
antly different from basal secretion (one way ANOVA followed by Dunnett's test, with a
Fig. 5. Effect of a MAPK/JNK pathway inhibitor on cytokine-induced S100B secretion.
C6 glioma culture cells were exposed to 10 ng/mL IL-1β, TNF-α, IL-6 or IL-8 for 1 h,
in the presence (or not) of 10 μM SP600125 (MAPK/JNK inhibitor), added 15 min be-
fore cytokine exposure. S100B content in the medium was measured by ELISA. Each
value is the mean (± standard error) of 6 independent experiments performed in trip-
licate. Means indicated by different letters are signiﬁcantly different. a Signiﬁcantly dif-
ferent from basal secretion. b Signiﬁcantly different from cytokine induced secretion
(one way ANOVA followed by Tukey's test, with a signiﬁcance level of pb0.05).
Fig. 3. Effect of a MAPK/ERK pathway inhibitor on cytokine-induced S100B secretion.
C6 glioma culture cells were exposed to 10 ng/mL IL-1β, TNF-α, IL-6 or IL-8 for 1 h,
in the presence (or not) of 10 μM PD98059 (MAPK/ERK inhibitor), added 15 min be-
fore cytokine exposure. S100B content in the medium was measured by ELISA. Each
value is the mean (± standard error) of 6 independent experiments performed in trip-
licate. Means indicated by different letters are signiﬁcantly different. a Signiﬁcantly dif-
ferent from basal secretion. b Signiﬁcantly different from cytokine-induced secretion
(one way ANOVA followed by Tukey's test, with a signiﬁcance level of pb0.05).
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IL-6-induced S100B secretion (pb0.0001). Clozapine did not change
the effect of IL-6 on S100B secretion (p=0.474). Interestingly, risperi-
done per se increased basal S100B secretion. Moreover, risperidone
prevented the IL-6 induced S100B secretion, resulting in secretion to
levels that were lower than those at basal conditions.
Acute ROS production induced by IL-6 is prevented by haloperidol.
To assess the effect of antipsychotic drugs in intracellular ROS pro-
duction on C6 glioma cells exposed to IL-6, we added haloperidol, ris-
peridone and clozapine (Fig. 10). Haloperidol abolished IL-6-induced
ROS production (pb0.05). Neither clozapine nor risperidone were
able to prevent the effect of IL-6 on DCF levels (p=0.59 and p=
0.32, respectively). Moreover, risperidone and clozapine per se acute-
ly increased basal DCF levels (pb0.001 and pb0.05, respectively).
4. Discussion
Several lines of evidence indicate that glial dysfunction could be a
pathogenic factor in schizophrenia. Levels of S100B, a protein expressed
and secreted by glial cells, astrocytes (mainly) and oligondrocytes
(Donato et al., 2009; Steiner et al., 2008), are altered in the serum and
CSF of schizophrenic patients, reinforcing this idea (Schroeter and
Steiner, 2009). Themechanism of S100B secretion is unknown, but neu-
rotransmitters including glutamate (Buyukuysal, 2005; Goncalves et al.,Fig. 4. Effect of a MAPK/p38 pathway inhibitor on cytokine-induced S100B secretion.
C6 glioma culture cells were exposed to 10 ng/mL IL-1β, TNF-α, IL-6 or IL-8 for 1 h,
in the presence (or not) of 10 μM SB203580 (MAPK/p38 inhibitor), added 15 min be-
fore cytokine exposure. S100B content in the medium was measured by ELISA. Each
value is the mean (± standard error) of 6 independent experiments performed in trip-
licate. Means indicated by different letters are signiﬁcantly different. a Signiﬁcantly dif-
ferent from basal secretion. b Signiﬁcantly different from cytokine induced secretion
(one way ANOVA followed by Tukey's test, with a signiﬁcance level of pb0.05).2000; Tramontina et al., 2006), serotonin (Tramontina et al., 2008), do-
pamine (Nardin et al., 2011) and acetylcholine (P. Lunardi, unpublished
data) are able to modulate its secretion in cell cultures and acute brain
slices.
However, increments in serum and CSF S100B in schizophrenic
patients cannot be explained exclusively by changes in the proﬁle of
S100B secretion, caused by altered neurotransmission. For example,
assuming that D2 receptors in astrocytes of these preparations are
negatively coupled to adenylcyclase, a decrease in S100B secretion
would be expected (Nardin et al., 2011). Recent ﬁndings, in animal
models and human studies, have provided cumulative evidence for
the cytokine hypothesis of schizophrenia (Watanabe et al., 2010). In
addition, a correlation between S100B and pro-inﬂammatory mole-
cules has been demonstrated in neurological and psychiatric disor-
ders (Ashraf et al., 1999; Pleines et al., 2001; Potvin et al., 2008).
Supporting an inﬂammatory role for S100B, we have observed
changes in S100B secretion in response to interleukin-1β (de Souza
et al., 2009) and activation of TLR4 (Guerra et al., 2011). Furthermore,
inﬂammatory cytokines were found to stimulate S100B secretion in
hippocampal slices and this effect was conﬁrmed in C6 glioma cells.
The effect on S100B secretion was acute, since no effect was observed
at 6 or 24 h after cytokine exposure in cell cultures. We previously
demonstrated cytokine-mediated modulation of S100B secretion in
primary astrocytes and C6 glioma cells (de Souza et al., 2009).
Grifﬁn et al. (1998) previously reported an increase in S100BFig. 6. Effect of a NF-κB inhibitor on cytokine-induced S100B secretion. C6 glioma culture
cells were exposed to 10 ng/mL IL-1β, TNF-α, IL-6 or IL-8 for 1 h, in the presence (or not)
of 50 μg/mL SN-50 (NF-κB inhibitor), added 15 min before cytokine exposure. S100B con-
tent in themediumwas measured by ELISA. Each value is themean (± standard error) of
6 independent experiments performed in triplicate. Means indicated by different letters
are signiﬁcantly different. ⁎ Signiﬁcantly different from basal secretion (one way ANOVA
followed by Tukey's test, with a signiﬁcance level of pb0.05).
Fig. 7. Intracellular GFAP and S100B content are modiﬁed by cytokines in C6 glioma cells. C6 glioma cells exposed to 10 ng/mL IL-1β, TNF-α, IL-6 or IL-8 for 24 h were lysed and
intracellular contents of S100B (A) and GFAP (B) were measured by ELISA. The line indicates basal secretion, assumed as 100% in each experiment. In C, C6 glioma cells were ex-
posed to 10 ng/mL IL-6 for 24 h, phase-contrast images from control and IL-6-exposed cells are shown in panels A and B, respectively; immunocytochemistry for S100B from con-
trol and IL-6-exposed cells are shown in panels C and D, respectively; and immunocytochemistry for GFAP in control and IL-6-exposed cells are shown in panels E and F,
respectively. Each value is the mean (± standard error) of at least 5 independent experiments performed in triplicate.⁎ Signiﬁcantly different from basal secretion (one way
ANOVA followed by Tukey's test, with a signiﬁcance level of pb0.05). Scale bar=20 μm.
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crease in the intracellular content of this protein. Nonetheless, we
know now that an increase in cell content of this protein is not neces-
sarily accompanied by its secretion (de Souza et al., 2009). An in-
crease in extracellular S100B was also observed in cell cultures
exposed to TNF-α (Edwards and Robinson, 2006). However, these au-
thors also observed an increase in extracellular GFAP, suggesting that,
under the conditions used, TNF-α exposure affected cell integrity. Con-
versely, S100B appears to modulate expression (and release) of TNF-α
and IL-6 (Ponath et al., 2007); suggesting a new role for IL-6 in stimulat-
ing S100B release. Our data clearly indicate that S100B secretion is stim-
ulated by the inﬂammatory cytokines, IL-1β, TNF-α, IL-6 and IL-8,
suggesting that the increase in S100B observed in schizophrenic pa-
tients could, in part, be explained by cytokine stimulation.
Our next step was to investigate the signaling pathway involved in
this mechanism, in particular the MAPK pathway, which is implicated
in gene expression as well as in the molecular mechanisms of protein
secretion, in response to a diverse range of extracellular stimuli. The
MAPK pathway, in fact, encompasses three distinct pathways; the
ERK, p38 and JNK pathways. Speciﬁc inhibitors of these pathways
were able to block the S100B secretion induced by inﬂammatory cy-
tokines. It is important to mention that these signaling kinases are
susceptible to oxidative stress (Gaitanaki et al., 2003). Therefore, the
oxidative stress observed in schizophrenic patients and other brain
disorders could modulate S100B secretion through MAPK. Moreover,
under the conditions used, cytokines were able to induce oxidative
stress, as shown by measurements of DCF oxidation and reduced glu-
tathione content. In general, cytokines induced oxidative stress, but
not nitrosative stress (based on measurement of nitrate content);
however, IL-6 was not able to modify glutathione content and IL-8
did not affect DCF oxidation. These ﬁndings may help to explain the
presence of markers of oxidative stress and the impaired antioxidant
defense system previously found in patients with schizophrenia
(Martinez-Cengotitabengoa et al., 2012).The NF-κB pathway was also investigated using SN-50, an inhibi-
tor for the nuclear migration of this transcription factor. No effect
was observed on IL-6-induced S100B secretion. Moreover, SN-50 per
se caused an increase in S100B secretion. The increase in S100B secre-
tion that we observed, induced by SN-50, could be interpreted as in-
terruption of the tonic inhibition of NF-κB-mediated S100B synthesis.
In fact, NF-κB-mediated activation of transcription has been widely
characterized, but the mechanisms of NF-κB-mediated repression
have not (Tchivileva et al., 2009). However, to our knowledge, a di-
rect involvement of NF-kappaB in S100B expression has not been
reported. Moreover, the effects of MAPK and NF-kappa B inhibitors
on S100B secretion (measured in 1 h) possibly do not involve protein
synthesis. Therefore, the effect of SN-50 may involve target(s) other
than NF-κB (Torgerson et al., 1998).
IL-6 was able to induce an increase in GFAP and S100B 24 h after-
wards. In fact, IL-6 is an important regulator of neuroinﬂammation
and contributes to astrocytic differentiation of C6 glioma cells
(Takanaga et al., 2004). Increased blood levels of IL-6 cytokine in
schizophrenia have been described over 20 years (Shintani et al.,
1991) and this cytokine has been used in schizophrenia models
(Behrens et al., 2008). However, postmortem human brain studies in-
dicate a lack of gliosis in most schizophrenic brains (Arnold et al.,
1996; Damadzic et al., 2001). On the other hand, it is possible that
cytokine-induced gliosis could be transitory, as observed in animal
models (Fatemi and Folsom, 2009). Moreover, it is necessary to con-
sider the effect per se on GFAP of chronic antipsychotic administra-
tion, which in rats was dependent on type of antipsychotic and
brain region (Blazquez Arroyo et al., 2010).
Wehave chosen IL-6-induced S100B secretion to evaluate the effects
of the antipsychotics, haloperidol, clozapine and risperidone. Exposure
of C6 and OLN-93 cells to haloperidol and clozapine caused a decrease
in basal S100B release (Steiner et al., 2008); the authors of this report
suggested that serum S100B elevation in schizophrenic patients is nor-
malized rather than increased by the effects of antipsychotic drugs on
Fig. 8. Signals of oxidative stress are observed in C6 glioma cells exposed to cytokines
for 1 h or 24 h. Intracellular ROS production (A) and nitric oxide production (B) were
measured in the C6 cell line in the absence and in the presence of 10 ng/mL IL-1β,
TNF-α, IL-6 or IL-8 after 1 h of treatment. Glutathione amount (C) was quantiﬁed at
24 h. In A, the line indicates basal secretion, assumed as 100%. Each value is the
mean (± standard error) of at least 5 independent experiments performed in tripli-
cate.* Signiﬁcantly different from control (one way ANOVA followed by Tukey's test,
with a signiﬁcance level of pb0.05).
Fig. 9. Increase of S100B secretion induced by IL-6 in C6 glioma cells is prevented by
antipsychotics. C6 glioma culture was exposed to 10 ng/mL IL-6 for 1 h, in the presence
or in the absence of haloperidol (0.3 μM) or risperidone (70 nM) or clozapine (3 μM),
added 15 min before cytokine exposure. S100B content in the medium was measured
by ELISA. The line indicates basal secretion, assumed as 100% in each experiment. Each
value is the mean (± standard error) of 6 independent experiments performed in trip-
licate. a Signiﬁcantly different from basal secretion. b Signiﬁcantly different from cyto-
kine induced secretion. c Signiﬁcantly different from risperidone induced secretion
(one way ANOVA followed by Tukey's test, with a signiﬁcance level of pb0.05).
Fig. 10. IL-6-induced intracellular ROS production in C6 glioma cells is prevented by halo-
peridol. Intracellular ROS production was measured in C6 glioma cultures exposed to
10 ng/mL IL-6 for 1 h, in thepresence or in the absence of haloperidol (0.3 μM), risperidone
(70 nM) or clozapine (3 μM), added 15 min before cytokine exposure. Each value is the
mean (± standard error) of 4 independent experiments performed in triplicate. a Signiﬁ-
cantly different from basal secretion. b Signiﬁcantly different from cytokine-induced secre-
tion. c Signiﬁcantly different from risperidone-induced secretion (onewayANOVA followed
by Tukey's test, with a signiﬁcance level of pb0.05).
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hippocampal slices and C6 cells, induced by apomorphine (Nardin et
al., 2011); in contrast, antipsychotics (haloperidol and risperidone)
were not able to alter this change. In the present study, we demonstrat-
ed that S100B secretion, induced by IL-6, is prevented by haloperidol
and risperidone, but not clozapine. Only risperidonewas able to change
basal S100B secretion, conﬁrming a previous study (Quincozes-Santos
et al., 2008). Together these data reinforce the idea that antipsychotics
help to normalize the elevated serum S100B levels in schizophrenic pa-
tients, during acute active phases and that cytokines are underlying
these S100B elevations. It should be noted that adipocytes are another
important source of serum S100B (Goncalves et al., 2010) and that
major metabolic changes in schizophrenic patients are observed in
these cells (Steiner et al., 2010a).
However, the effect of antipsychotic drugs on IL-6-induced S100B
secretion in C6 glioma cells indicates a modulation via D2 receptors. It
isworthmentioning that atypical antipsychotic drugs, such as clozapine
and risperidone, involve more 5HT2A than D2 (Kuroki et al., 2008).
Moreover, other receptors such as 5HT7, found in astrocytes, are targets
of antipsychotic drugs and putatively could underlie the differentmodulations observed with clozapine and risperidone (Smith et al.,
2011). Therefore, these and other receptors are modulating basal and/
or cytokine-induced S100B secretion in brain tissue, making it difﬁcult
to describe a simple scenario to explain the extracellular changes of
this protein. Moreover, the effects of antipsychotic drugs on S100B se-
cretion could be due to changes in cell oxidative status (Donato et al.,
2009). However, for haloperidol, in contrast to its in vivo long term ad-
ministration (Pillai et al., 2007), we observed a decrease in ROS levels in
gliomaC6 cells at 1 h after administration.Moreover, we know that hal-
operidol, at high concentrations (but not risperidone), is able to induce
ROS production after 6 h (Quincozes-Santos et al., 2010) in C6 glioma
cells. Therefore, it was not possible to correlate S100B secretion and
ROS levels in C6 glioma cells during acute exposure to antipsychotic
drugs.
Some limitations of this study should be noted. Firstly, this is an in
vitro study, useful for studying responses andmechanisms in an isolated
manner, but unable to demonstrate the entire complexity of a system in
vivo. Secondly, levels of S100B secretion found are sub-nanomolar
levels compatible with the neurotrophic activity of this protein ob-
served in culture; however, the speciﬁc effects of the increased secre-
tion of this protein following the stimulation of neurons and other
21D.F. de Souza et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 43 (2013) 14–22neuronal cells with pro-inﬂammatory cytokines should be studied. Fi-
nally, it is worth mentioning that although the astrocytes are the main
source of extracellular S100B, the contribution of other cells should
not be excluded, particularly in slice preparations. However, our ability
to reproduce previous results validates our preparations for compara-
tive approaches.5. Conclusions
Our data provides evidence that S100B secretion is increased by
pro-inﬂammatory cytokines in C6 glioma of cells and hippocampal
slices of rats via MAPK, and that oxidative stress may be a component
of this modulation. IL-6 induced an increase of S100B and GFAP. These
results reinforce the idea that the S100B protein is involved in the in-
ﬂammatory response observed inmanybrain diseases including schizo-
phrenia. Moreover the antipsychotics, haloperidol and risperidone,
were able to inhibit the secretion of S100B following IL-6 stimulation.Acknowledgments
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